These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7515649)
1. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Kimby E; Björkholm M; Gahrton G; Glimelius B; Hagberg H; Johansson B; Johansson H; Juliusson G; Järnmark M; Löfvenberg E Ann Oncol; 1994; 5 Suppl 2():67-71. PubMed ID: 7515649 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196 [TBL] [Abstract][Full Text] [Related]
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
5. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885 [TBL] [Abstract][Full Text] [Related]
7. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680 [TBL] [Abstract][Full Text] [Related]
8. [Low-grade non-Hodgkin's lymphomas. Study of 73 cases]. Coma A; Jonte F; Zanabili Y; Soto I; Fanjul F; Carrera D; Rayón C; Luño E; Jalón S; Pinto V Sangre (Barc); 1992 Aug; 37(4):249-54. PubMed ID: 1514137 [TBL] [Abstract][Full Text] [Related]
9. Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study. Bergmann L; Karakas T; Lautenschlager G; Jager E; Knuth A; Mitrou PS; Hoelzer D Ann Oncol; 1995 Dec; 6(10):1019-24. PubMed ID: 8750155 [TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin's lymphoma in the elderly: the impact of advanced age on therapeutic options and clinical results. Orlandi E; Lazzarino M; Brusamolino E; Castelli G; Pagnucco G; Morra E; Bernasconi C Haematologica; 1991; 76(3):204-8. PubMed ID: 1743590 [TBL] [Abstract][Full Text] [Related]
11. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500 [TBL] [Abstract][Full Text] [Related]
12. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
13. [Weekly CHOP chemotherapy in the treatment of intermediate-grade non-Hodgkin's lymphomas--cooperative group study by seven institutes]. Kobayashi M; Sao H; Mizuta S; Kamiya O; Ohara K; Nagata K; Takeyama H; Watanabe E; Yamada H; Mizuno H Rinsho Ketsueki; 1990 Oct; 31(10):1656-63. PubMed ID: 2255056 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771 [TBL] [Abstract][Full Text] [Related]
15. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma]. Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718 [TBL] [Abstract][Full Text] [Related]
16. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Tirelli U; Errante D; Van Glabbeke M; Teodorovic I; Kluin-Nelemans JC; Thomas J; Bron D; Rosti G; Somers R; Zagonel V; Noordijk EM J Clin Oncol; 1998 Jan; 16(1):27-34. PubMed ID: 9440719 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435 [TBL] [Abstract][Full Text] [Related]
18. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521 [TBL] [Abstract][Full Text] [Related]
19. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
20. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study . Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S; Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]